Gilead Sciences
GILD· Manufacturing· Fiscal year ends in December
Daniel P. O’Day is the CEO of Gilead Sciences and was paid $28.4M in FY2025 (Dec), up 20%.
Executives5
See all- 1Daniel P. O’DayChairman and Chief Executive OfficerFY2025
- 2Dietmar BergerM.D., Ph.D. Chief Medical OfficerFY2025
- 3Johanna MercierChief Commercial and Corporate Affairs OfficerFY2025
- 4Andrew D. DickinsonChief Financial OfficerFY2025
- 5Deborah H. TelmanFormer Executive Vice President, Corporate Affairs and General CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allGilead Sciences paid its 5 named executives $65.4M in total in FY2025 (Dec). CEO Daniel P. O’Day was paid $28.4M of that.
| Name | |||
|---|---|---|---|
| Daniel P. O’DayChairman and Chief Executive Officer | |||
| Dietmar BergerM.D., Ph.D. Chief Medical Officer | Not disclosed | Not disclosed | |
| Johanna MercierChief Commercial and Corporate Affairs Officer | |||
| Andrew D. DickinsonChief Financial Officer | |||
| Deborah H. TelmanFormer Executive Vice President, Corporate Affairs and General Counsel |
of each named executive, from the Summary Compensation Table of each proxy.
Peers10
See allThe FY2025 (Dec) proxy of Gilead Sciences names 10 peer companies for pay. Among Gilead Sciences and these peers, CEO pay was 4th highest of 9 and total shareholder return was 3rd highest of 9.
4th highest of 9in Gilead Sciences and its pay peers, FY2025 (Dec) by CEO pay:
3rd highest of 9in Gilead Sciences and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- Sandra J. HorningDirector · 3 yr on the boardIndependentNominating and Corporate Governance, Science (Chair)—Paid as an executive
- Ted W. LoveDirector · -1 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2023).
Activity
Filings23
See all| Current report | 8-K | May 4, 2026 | — |
| Proxy statement | DEF 14A | Mar 20, 2026 | FY2025 |
| Annual report | 10-K | Feb 24, 2026 | FY2025 |
| Current report | 8-K | Nov 19, 2025 | — |
| Current report | 8-K | Aug 14, 2025 | — |
| Current report | 8-K | May 8, 2025 | — |